NYSEAMERICAN:NBY - Novabay Pharmaceuticals Stock Price & Analysis

About Novabay Pharmaceuticals (NYSEAMERICAN:NBY)

(NYSEAMERICAN:NBY) NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Stock Price

Statistics Highlights (NYSEAMERICAN:NBY)

Shares Outstanding	52.62M	Beta	3.31
Public Float	42.06M	P/E Ratio	-
% Short of Float	-	Dividend (Yield)	-
Held by Insiders	20.17%	Ex-Dividend Date
Held by Institutions	3.03%	IPO Date	Oct 26, 2007

Explore More on "Statistics" Section

NBY Financial Summary

|

	Dec 21	Dec 20	Dec 19
Revenue	$8.42M	$9.93M	$6.60M
EBITDA	$-5.71M	$-10.98M	$-9.59M
Net Income	$-5.82M	$-11.04M	$-9.66M
Total Assets	$23.98M	$15.24M	$11.22M
Total Cash	$7.50M	$11.95M	$6.94M
Total Debt	$551.00K	$174.00K	$4.05M

	Mar 22	Dec 21	Sep 21
Revenue	$2.63M	$2.64M	$1.84M
EBITDA	$10.00K	$-71.00K	$-2.28M
Net Income	$-111.00K	$-158.00K	$-2.29M
Total Assets	$24.79M	$23.98M	$12.24M
Total Cash	$5.64M	$7.50M	$9.03M
Total Debt	$2.39M	$551.00K	$196.00K

NBY Stock Price History

Novabay Pharmaceuticals Annual Stock Price History

Year	Open	Close	Change
2021	$0.39	$0.26	-32.19%
2021	$0.72	$0.39	-46.09%
2020	$0.63	$0.72	14.33%

Novabay Pharmaceuticals Daily Stock Price History

Date	Open	High	Low	Close	Change	Volume
Jun 9, 2022	$0.23	$0.25	$0.22	$0.23	17.04%	1.12M
Jun 22, 2022	$0.20	$0.21	$0.20	$0.20	-9.15%	376.68K
Jun 13, 2022	$0.21	$0.23	$0.19	$0.22	2.41%	617.09K

View More on "Price History" Section

(NYSEAMERICAN:NBY) Stock Price FAQs

What is today's stock price of Novabay Pharmaceuticals (NYSEAMERICAN:NBY)?

The current stock price of Novabay Pharmaceuticals (NYSEAMERICAN:NBY) is $0.26.
Today NBY stock price opened at $0.26 after previous close of $0.26.
During the day, Novabay Pharmaceuticals stock quote has varied from a low of $0.25 to a high of $0.29.

What is Novabay Pharmaceuticals's 52-week change?

NBY 52-week high stock quote is $0.77, which is 192.40% above the current share price.
The Novabay Pharmaceuticals (NYSEAMERICAN:NBY) 52-week low stock price is $0.17, which is 35.40% below the current share price.
Novabay Pharmaceuticals share price volatility (52-week beta) is 3.31.

Is Novabay Pharmaceuticals a buy?

According to 2 analysts, the current consensus recommendation for Novabay Pharmaceuticals stock is "Strong Buy" at an average rating score of 5.00 (out of 5).
There are currently 2 "Strong Buy", 0 "Buy", 0 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the NBY stock.
The 12 month average price target forecast for NBY stock is $3.10, representing a 1077.40% increase from the current NBY stock price of $0.26.

Novabay Pharmaceuticals (NYSEAMERICAN:NBY) FAQ

How Much is Novabay pharmaceuticals Worth?

Novabay pharmaceuticals's worth today based on market capitalisation is $13.85M

How much dividend does Novabay pharmaceuticals Pay?

The current annualized dividend payout for NBY stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Novabay pharmaceuticals's "Dividend" Section

When is the next earnings date for Novabay pharmaceuticals (NYSEAMERICAN:NBY)?

Novabay pharmaceuticals is expected to report earnings on November 09 ,2022.
View More Details on Novabay pharmaceuticals's 'Earnings' Section

What is Novabay pharmaceuticals’s Price to Earning (PE) ratio?

NBY stock also has a Price to Sales (P/S) ratio of 1.50, a Price to Book of 0.68 and Price/Earnings to Growth (PEG) of 0.00.

What is the Novabay pharmaceuticals's ticker?

Novabay pharmaceuticals trades on the NYSE American stock market in USA under the ticker symbol "NBY". Novabay pharmaceuticals’s stock symbol can also be displayed as "NYSEAMERICAN:NBY".

When did NBY go public?

Novabay pharmaceuticals completed its initial public offering (IPO) on October 26 ,2007.

Who are the owners of Novabay pharmaceuticals?

Novabay pharmaceuticals (NYSEAMERICAN:NBY) is owned by 3.02% institutional shareholders and by 20.17% insiders. The rest is owned by the public.
Explore More Details on Novabay pharmaceuticals's “Ownership” Section

Who are the key executives of Novabay pharmaceuticals (NBY)?

Novabay pharmaceuticals's key executive team includes the following managers:

Mr. Justin M. Hall Esq., Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director (1978)
Mr. Andrew D. Jones, CFO & Treasurer (1971)
Dr. Audrey Kunin M.D., Chief Product Officer & Director (1959)
Dr. Jeffrey Kunin M.D., Pres of DERMAdoctor (1963)

What is Novabay pharmaceuticals’s Sector & Industry Classification?

Novabay pharmaceuticals (NYSEAMERICAN:NBY) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Novabay pharmaceuticals?

Currently the number of employees working for Novabay pharmaceuticals is 29.

Where are Novabay pharmaceuticals's Headquarters?

Novabay pharmaceuticals (NYSEAMERICAN:NBY) is headquartered in CA, United States.

What are Novabay pharmaceuticals's Address and Phone Number?

Novabay pharmaceuticals’s mailing address is 2000 Powell Street, EmeryVille, CA, United States, 94608.
The company’s phone number is 510 899 8800.

What is the official website for Novabay pharmaceuticals?

Novabay pharmaceuticals’s official website is http://www.novabay.com

NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)